Listed biotechnology firm听e-therapeutics听has raised 拢22.5听million in a conditional share placing.
The Newcastle University spin-out last year听expanded into RNA interference as a therapeutic modality to pursue drug discovery outcomes.
Former long-time CEO of Silence Therapeutics and former professional chess player Ali Mortazavi is credited with a successful reorganisation of the business last year.
He became CEO and chairman in October but stepped down from the latter position recently as the roles were split.
Professor Trevor Jones, a non-executive director at the firm since 2015, became the new chair.
Last year Mortazavi听oversaw a听raise听of听拢11.6m听growth funding to expand its platform capabilities,听asset pipeline, team and relocate its听head office听in听Oxford听鈥� where it is now based听鈥撎�and听open a new London base.听